A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

NCT01077622 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukaemia, Lymphocytic, Chronic

Interventions

DRUG: ofatumumab 100 mg, 1000 mg / vial

Sponsor

GlaxoSmithKline